dendritic cell fusion vaccine

A dendritic cell fusion vaccine is a personalized cancer immunotherapy created by fusing autologous (patient-derived) dendritic cells with tumor cells from the same patient. This process generates hybrid cells that present a broad spectrum of tumor-associated antigens in the context of potent antigen presentation and costimulatory signals provided by the dendritic cells. The resulting fused cells are administered as a therapeutic cancer vaccine to stimulate robust anti-tumor immune responses, particularly activating both CD4+ helper and CD8+ cytotoxic T lymphocytes against the patient's own cancer. Dendritic cell fusion vaccines have been investigated primarily for hematologic malignancies such as multiple myeloma and acute myeloid leukemia (AML), where they have shown feasibility, safety, induction of tumor-specific immunity, and evidence of disease stabilization or improved progression-free survival in early-phase clinical trials[3][6][8]. The mechanism relies on enhanced antigen presentation leading to expansion of tumor-reactive T-cell clones.

Other names

DC/tumor fusion vaccineDC/MM fusion vaccineDC/AML fusion vaccinedendritic cell/tumor fusion cell vaccine